18.09.2012 - UCB S.A. has officially opened the doors to a new pilot biotech plant at its Braine-L'Alleud site in Belgium.
The Brussels-based drugmaker has invested more than €65m into the project, which was supported by the Walloon region. The 5,100 square meter facility is currently undergoing a validation phase. After becoming fully operational in the course of 2013, the first four bioreactors with a total volume of 3,200 litres will start to produce cell culture-based therapeutic proteins for UCB’s research pipeline and clinical trials. At the same time, manufacturing processes will be designed and optimised to move from development to full scale industrial production. The facility will include integrated laboratories and additional infrastructure to house 100 staff.
“Today, 33% of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB’s current R&D pipeline“, stated Roch Doliveux, CEO of UCB. “With this bio pilot plant, we can more rapidly initiate clinical studies of new antibody-based therapeutics that are addressing serious unmet medical needs.”
UCB is currently heavily investing to push its production capabilities. Just last year, the Belgian company also initiated a project to build in-house biotech microbial manufacturing capacity in Bulle, Switzerland. The new manufacturing unit is expected to become operational in 2015 and requires an investment of €250m.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more